Belgium· BE-AMP-SAM665720-00
Kyinsu 700 U/ml - 2 mg/ml
A insulin icodec und semaglutid product containing insulin icodec, registered in Belgium by Novo Nordisk. The same ATC class is registered in 6 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Insulin icodec und semaglutid is registered in 6 of 19 countries.
Countries holding a registration under ATC A10AE57 (insulin icodec und semaglutid), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 4 of them publish a price we can compare per daily dose
Insulin icodec und semaglutid · ATC A10AE57
6 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Insulin Icodec
- Manufacturer
- Novo Nordisk
- Country
- Belgium (BE)
- ATC code
- A10AE57
- ATC class
- Insulin Icodec und Semaglutid
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulin icodec und semaglutid in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAWIQLINovo Nordisk A/S, Bagsvaerd
- SwitzerlandAwiqli FlexTouch 700 E/ml, Injektionslösung im FertigpenNovo Nordisk Pharma AG
- United StatesAwiqliNovo Nordisk
- CanadaAWIQLINOVO NORDISK CANADA INC
- Japanインスリン イコデク（遺伝子組換え）ノボ ノルディスク ファーマ
- ItalyAWIQLI*1 penna preriempita SC 700 U/ml 1,5 ml + 14 aghiNOVO NORDISK A/S
- IcelandAwiqliNovo Nordisk A/S*
- FinlandAwiqliNovo Nordisk A/S
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Awiqli
- Norway · Awiqli
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b2f0758c-c8f4-4903-a671-af6a65ca71c3 GET /v1/drugs/b2f0758c-c8f4-4903-a671-af6a65ca71c3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled pen",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Kyinsu 700 U/ml - 2 mg/ml",
"name_fr": "Kyinsu 700 U/ml - 2 mg/ml",
"name_nl": "Kyinsu 700 U/ml - 2 mg/ml",
"amp_code": "SAM665720-00",
"strengths": [
"700.0000",
"700.0000",
"2.0000",
"2.0000"
],
"pack_count": 2,
"substances": [
"Insulin Icodec",
"Semaglutide",
"Glycerol",
"Sodium Chloride",
"Sodium Hydroxide"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Insulin Icodec and Semaglutide",
"authorisation_numbers": [
"EU/1/25/1992/006",
"EU/1/25/1992/005"
]
}See everything about insulin icodec und semaglutid.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.